TW200942181A - Nutrition composition for inhibiting high blood glucose - Google Patents

Abstract

Disclosed is a nutritional composition for preventing hyperglycemia, which comprises a nitrogen source, a lipid and a sugar component, wherein the nitrogen source comprises free isoleucine and/or free leucine, the lipid comprises a middle-chain fatty acid triglyceride, and the sugar component comprises palatinose and/or trehalose. The nutritional composition has an excellent nutritional balance even when the nutritional composition is ingested for a long period, can prevent the development of hyperglycemia after the nutritional composition is administered, and enables the reduction in the amount of insulin to be administered.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a nutritional composition excellent in nutrient balance with a high blood sugar suppressing action. [Prior Art] 0

In addition to maintaining human life, amino acids are essential for creating a daily lifestyle that is essential for a pleasant and comfortable life. However, because it has a therapeutic effect on various diseases, it has been used as an effective ingredient in medicines, nutrients or supplements. For example, a drug for preventing sugar abnormality and foods and drinks containing at least one of leucine, isoleucine, and valine are proposed (Patent Documents 1 and 2). In the publications, the only ones used in the examples were leucine or a mixture of leucine, isoleucine and valine, and the rats were orally administered with 1.5 g/kg. Changes in blood glucose levels when measured. Therefore, this sugar-tolerant drug-specific agent is particularly effective for treating, ameliorating, and/or preventing the sugar-resistant abnormality of a liver disorder which is difficult to use in the conventional diabetes drug. Isocetulose (palatinose) and trehalose are one type of saccharide, and are proposed to be used as an essential component of a nutritional composition for controlling blood sugar sputum (Patent Document 3). In the present invention, the isomaltulose and/or sea-thream sugar in the energy ratio of the saccharide is 60 to 100%, and the inventors of the present invention investigate the blood sugar sputum control effect of isomaltulose. It was confirmed that if the amount of isomaltulose which is 68.5 mass% or more of the saccharide is not used, the effect of suppressing the increase in blood sugar 异 of isomaltulose cannot be sufficiently exhibited (see FIG. 1). -5- 200942181 On the other hand, it is proposed to use a liver-defective disorder containing one or more kinds of branched-chain amino acids and isomaltulose which are selected from the group consisting of leucine, isoleucine and valine. Nutritional composition (Patent Document 4). In the embodiment of the present invention, when isomaltulose is used in an amount of 75% by mass of the saccharide, the saccharide is burned more slowly and has better characteristics. Even if any of the above-mentioned various nutrient compositions exhibits an effect of suppressing the blood sugar sputum, the long-term ingestion, in particular, the digestion and absorption of the saccharide is deteriorated, and the nutritional balance becomes large. For patients with hyperglycemia, their nutritional limitations are generally instructed. Among the three major nutrients, especially the highly efficient saccharide as an energy matrix is limited by the correction of hyperglycemia. In such a case, if the above-mentioned isomaltulose and trehalose which are absorbed very slowly by the intestinal tract are used in a large amount, it is difficult to sufficiently supply energy necessary for maintaining protein synthesis or maintenance of the body, and if the state is maintained for a long period of time, It is said that there is a situation of falling into a low nutritional status. Therefore, it is recommended to take a prudent response to the nutrition guidance, and it is recommended to provide a nutrient composition that takes into consideration appropriate energy in order not to cause malnutrition when the diet is administered to an elderly person (Non-Patent Document 1). However, with regard to nutritional therapy, it is eagerly desired to have a nutrient composition which can reduce blood sugar sputum and which is excellent in nutritional balance and can efficiently supply energy. On the other hand, with the increase in diabetes, the number of patients with diabetes mellitus with diabetes mellitus has also increased. In recent years, the proportion of diabetic nephropathy in dialysis patients has exceeded 40%. It is also reported that the kidney disease is also the most common in the dialysis population (Non-Patent Document 2), and a kidney disease with hyperglycemia is also expected. The nutritional composition used by the patient. 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 Bulletin No. 350371 [Non-Patent Document 1] Based on the guidelines for the diagnosis and treatment of diabetes based on science, edited by the Diabetes Society, pp. 21-25, 2004, Nanjiang Hall

[Non-Patent Document 2] Statistical Research Committee of the Japan Dialysis Medical Association, Research Society, 41(1), 1, 2008. DISCLOSURE OF THE INVENTION An object of the present invention is to provide a nutritional composition which is excellent in nutritional balance even when taken for a long period of time, and which can suppress hyperglycemia after administration, and which can reduce the amount of insulin administered. Further, the object of the present invention is to provide a nutritional composition which can reduce the content of isomaltulose and/or trehalose in the saccharide, thereby reducing the absolute content of isomaltulose and/or trehalose. Further, the object of the present invention is to provide a nutritional composition for a patient suffering from a kidney disease suffering from hyperglycemia. The present invention is based on the discovery that if a free isoleucine and/or free leucine, isomaltulose and/or trehalose, and a medium chain fatty acid triglyceride are used, an excellent hyperglycemic inhibitory effect can be obtained and obtained. The above-mentioned problem can be solved by reducing the nutritional composition of the nutrient composition and reducing the content of isomaltulose and/or trehalose in the saccharide, thereby reducing the absolute content of isomaltulose and/or trehalose. By. 200942181 That is, the present invention provides a nutritional composition for suppressing hyperglycemia, which is a nutrient composition containing a nitrogen source, a lipid and a saccharide, characterized in that the nitrogen source contains free isoleucine and/or free leucine The lipid contains a medium chain fatty acid triglyceride, and the saccharide contains isomaltulose and/or trehalose. [Embodiment] The free isoleucine and the free leucine used in the present invention may be any of an L-form, a D-form and a DL-form, but an L-form is preferably used. In particular, free isoleucine is used in the present invention. The free isoleucine or free leucine preferably contains 0.1 to 2.0 g per 100 kcal of the nutritional composition, and more preferably 0.3 to 1.5 g per 100 kcal of the nutritional composition. In the present invention, as the nitrogen source, free amino acids other than isoleucine and leucine, such as lysine and its salts, valine, arginine and its salts, amidoxime, Tryptophan, histidine and its salts, glycine, alanine, etc., but preferably the amount of isoleucine and/or leucine in the total nitrogen source is from 2% by mass to 100% by mass, especially It is preferably from 6% by mass to 80% by mass, and more preferably from 6% by mass to 40% by mass. In the present invention, in addition to the nitrogen source, a milk protein source such as skim milk powder or whole milk powder, casein or whey and a decomposition product thereof, collagen and a decomposition product thereof, and soybean protein or wheat protein may be used. A vegetable protein such as a decomposition product or a hydrolyzate (peptide) thereof. Further, the ratio of the nitrogen source to the solid content of the nutritional composition is preferably from 12 to 27 parts by mass per 100 parts by mass. In the present invention, a medium chain fatty acid triglyceride can be used as the lipid -8- 200942181, or a part thereof. Wherein, the medium chain fatty acid triglyceride is preferably a fatty acid residue of the fatty acid triglyceride having a carbon number of 6 to 12, particularly preferably the fatty acid residue constituting the fatty acid triglyceride has a carbon number of 8 And / or 10. The medium chain fatty acid triglyceride used in the present invention can be, for example, a commercially available one. The medium chain fatty acid triglyceride is excellent in energy efficiency, and its absorption rate is higher than that of general edible oil such as red scented oil or soybean oil which is formed by a fatty acid having 16 or more carbon atoms (long-chain fatty acid triglyceride). Faster is similar to sugar. Furthermore, in the tissues of the body, even if there is no medium like carnitine, the mitochondria can be burned as soon as possible in the body, and does not accumulate in the living body, and the amount of bio-energy generated is very high. Therefore, in order to prevent blood sugar from rising, the medium-chain fatty acid triglyceride, in addition to energy production, is not an essential amino acid necessary for maintaining the body's function, but it cannot maintain the body function. . Therefore, the specific mix ratio of the invention is important. On the other hand, since the long-chain fatty acid triglyceride of the above-mentioned general edible oil and fat is also fat, the calorie is high, and although the blood sugar is not increased, the cause of hyperlipemia and the cause of arteriosclerosis are caused by a large amount of long-term intake. Insulin resistance increases, which in turn promotes abnormal sugar tolerance. In the present invention, it is preferred that 1 to 75% by mass of the total lipid is medium chain fatty acid triglyceride, and particularly preferably 15% by mass to 60% by mass. Others use edible oils and fats. As edible fats and oils, in addition to palm oil, coconut oil, cottonseed oil, sunflower oil, peanut oil, perilla oil, almond oil, rapeseed oil, soybean oil, sunflower oil, olive oil, rice oil, corn oil, sesame oil, cocoa For example, vegetable oils such as butter, or animal fats such as butter, lard, fish oil, butter, and butter, etc., may be processed, such as margarine (shortening), and may be selected according to the use. use. These oils and fats, especially in the form of a large amount of water, are preferably emulsified by using an emulsifier such as a fatty acid monoglyceride or an organic acid monoglyceride, a polyglycerin fatty acid ester, a sucrose fatty acid ester or a lecithin. The dispersed state of the emulsion. Further, it is preferable to select an edible fat or oil, an emulsifier, and a use amount so that the ratio of the ω 6 -based fatty acid/ω3 fatty acid, which is an essential fatty acid, is 0.5 to 4.5. The proportion of the lipid is preferably from 9 to 27 parts by mass per 100 parts by mass of the solid content of the nutritional composition. In the present invention, as a part of the saccharide, isomaltulose and/or trehalose is used, and isomaltulose is preferred. The content of isomaltulose and/or trehalose in the saccharide is preferably 50% by mass or less, particularly preferably 5 to 40% by mass. Further, the absolute content of isomaltulose and/or trehalose is preferably from 0.5 to 7.5 g per 100 kcal of the nutritional composition in terms of nutritional balance. The saccharide source other than the above is not particularly limited, and examples thereof include commercially available proteins or their decomposition products (dextrin), sucrose, fructose, etc., which are used as an energy source and have excellent digestion and absorption. . Further, in the present invention, the ratio of the saccharide is preferably from 22 to 68 parts by mass per 100 parts by mass of the solid content of the nutritional composition. In the present invention, the mass of isomaltulose and/or trehalose relative to isoleucine and/or leucine is preferably 1/75 to 4/1, more preferably 1/50 to 2/1 〇. In the present invention, as a calorie source, in addition to a nitrogen source, a saccharide or a lipid of a protein, a peptide, an amino acid, etc., such as -10-200942181, it is also possible to use a variety of food materials for use as energy in a living body. Examples thereof include alcohols, a part of dietary fibers, oligosaccharides, organic acids and salts thereof. In addition to the use of these as calorie sources, it is also possible to provide stability, flavor enhancement, microbial countermeasures, pH adjustment, and three functions in the body for the supply of other nutrients, emulsification, color tone, rheology, etc. It can be selected and used according to various needs. Thus, by containing a specific amount of free isoleucine and/or free leucine, a specific amount of isomaltulose and/or trehalose, it can be observed that isomaltulose is separately taken. And/or the inhibition of the increase in blood sugar sputum by trehalose, and then by using a certain amount of medium-chain fatty acid triglyceride, before the sedition is used as a special effect, the first thing can be used to support the group. Be prepared for this. The rate of fructose effect can be low, but the cause of the increase is only 値 止 止 止 止 止 止 止 止 止 止 止 止 血 血 血 血 血 血 血 血 血 血 血 血 血 血 血 血 血 血 血 血 血 血 血 血 血 血 血 血% The nutrient composition of the present invention is a mineral or the like. As a dietary fiber, non-aqueous examples of water-soluble bran or crystalline cellulose such as galactomannan include vitamin A, vitamin B1, life B12, vitamin C, vitamin folic acid, carotene, pantothenic acid, and substances, for example, calcium. , phosphorus, copper, potassium, magnesium, iodine, etc. These may in addition contain dietary fiber, vitamins or examples of indigestible dextrin, pectin, fiber, and dietary fiber derived from soy or wheat. As a vitamin, vitamin B2, vitamin B6, vitamin K, vitamin D3, niacinamide, vitamin E, biotin, etc., as mineral zinc, manganese, chromium, molybdenum, selenium, iron, sodium as an organic acid salt or Inorganic acid salt, chemical -11 - 200942181 In addition to the food additives represented by synthetic products, etc., it is also possible to prepare extracts derived from various foods, yeast, etc., and various food materials. Further, in order to uniformly disperse the lipid or the like, a surfactant such as an emulsifier may be contained. The nutritional composition of the present invention can be further formulated with various natural or synthetic sweeteners, coloring agents, perfumes, and so-called functional auxins such as casein or lipoic acid. In recent years, if the hyperglycemia state caused by abnormal glucose metabolism such as diabetes persists, it is a problem to induce a reaction caused by excess active oxygen in the living body. The state in which the oxidation reaction is excessive is a cause of deterioration of diabetes mellitus such as atherosclerosis. Compared with the present invention, it is preferred to formulate vitamins or trace elements having antioxidant energy, such as vitamin carotene or retinol, vitamin Ε (tocopherol), vitamin C or zinc or selenium, in the present invention. . Further, it is further preferable to use other functional nutrients such as CoQ 10 having an antioxidant activity or polyphenols such as catechins, anthocyanins and isoflavones. According to the present invention, by adjusting the potassium and phosphorus contents, it is possible to provide a nutritional composition which can be appropriately nutritionally managed by reducing the risk of hyperglycemia even in patients with kidney diseases accompanied by hyperglycemia. The potassium content per 100 kcal of the nutrient composition of the kidney disease associated with such high blood sugar is preferably 35 to 155 mg, and more preferably 50 to 130 mg. Further, it is preferred that the phosphorus content per 100 kcal is 20 to 100 mg, more preferably 35 to 80 mg. In the future, diabetes continues to increase. The number of patients with diabetes in the elderly who are aging is increasing. In elderly patients with diabetes, nutritional management or nutritional supplementation in bed is also used to feed the nutrient composition into the stomach. In general, -12-200942181 elderly people have a small stomach volume, and therefore, in the case of such elderly people, a high concentration of a high nutritional composition is preferred. Therefore, it can be understood that the risk of hyperglycemia will increase if a high concentration of nutrients with a comprehensive nutritional supplement is added. Ο

The caloric concentration of the nutritional composition of the present invention is preferably from 5 kcal/ml to more than 1.5 kcal/ml, depending on the state of the patient. In particular, for elderly people with a small stomach volume or kidney disease patients with hyperglycemia, there is a limit to the nutrient composition or water content that can be administered or ingested, and it is preferably 1.5 kcal/ml or more. The upper limit is not particularly limited, but is preferably about 3.Okcal/ml. In the present invention, the calorie concentration is high and also high in nutrient value without causing hyperglycemia. In the present invention, by combining insulin stimulating substances and insulin-like substances, the effectiveness can be further enhanced. An example of free arginine is given as an example. The action of arginine on the pancreas/3 cells promotes insulin secretion. Up to now, it has not been considered that by using these substances and free isoleucine and/or free leucine, isomalt The ketose and/or trehalose and the medium chain fatty acid triglyceride have a better multiplying effect. Among the above-mentioned substances, if the above arginine is used as an example, it is preferably used in an amount of 克1 g to 20 g/lOOkcal, more preferably 0.1 g to 10 g/lOOkcal. Regarding the preparation of free arginine, it is not necessary for digestive action when administered orally or via a tube, for example, using free arginine, arginine hydrochloride, arginine nitrate, arginine sulfate, and fine A raw material in the form of an amino acid organic acid salt, a arginine glutamate, or a free arginine acid and a salt thereof. The nutritional composition of the present invention may be in the form of a powder, a granule, a plate, a strip, a gel or a liquid, but is preferably a liquid, especially 13-200942181 which is used in the intestine. The fluid food form is preferred. The nutrient composition of the present invention can be administered to the intestine or stomach directly by the administration of a liquid-like tube, and is administered to the stomach or the stomach. The cause of the symptoms. In this case, it is possible to adjust the viscosity of the composition to 500 mPa·s or more and 7,000 mPa·s (23 °C) by adding a tackifier or the like to the present invention, thereby reducing the risk of swallowing by the elderly, and how to increase the viscosity. According to the situation, when the nutrient composition is prepared to a high viscosity, it may be used by reducing or decreasing the viscosity. Further, in the present invention, it is also possible to select, to change the manufacturing steps, and to adjust the concentration of the preparation without adding a tackifier or the like! Use for 5-20,000 mPa · s ( 2 3 °C). On the other hand, in addition to diseases such as diabetes mellitus, which are abnormally caused by the blood sugar after the administration of the nutrient, most of the surgery is performed immediately after the surgery is performed, and the surgery becomes large, causing hyperglycemia and becoming surgery. After the nutrition management, the hyperglycemia before the operation is unmanageable and the surgical nutrient composition is not suitable for the nutrient recovery under the nutritional management of the above conditions. In addition, those with abnormal glucose tolerance are known to have reduced blood flow in vascular barrier blood vessels, and to reduce the supply of oxygen to the peripheral tissue, which may cause suture incompleteness after surgery, and to suffer from soreness in long-term bed rest. Therefore, the present invention can re-administer blood glucose while appropriately accommodating the patient. In particular, it is straight backwards and becomes the nutrition group of Ming. This situation is more than the following. Anymore. In addition, it is caused by the mechanical operation, by the raw material, etc., in addition to the simple. Ermen environment has become a problem. And. The hypoglycemia of the present invention is also particularly impeding. As a result, the capsule will occur in the form of nutrients, which can be used to prevent or cure acne and wounds. In the present invention, it is preferred to store in a container in a manner that at least 0.3 g of free isoleucine and/or free leucine is taken per administration. That is to say, if all the foods contained in the container are ingested, at least 0.3 g of free isoleucine and/or free leucine may be produced in the stomach of the human body.

When the nutritional composition of the present invention is in the form of a flowing food for enteral use, it is preferably contained in a container having a capacity of 50 to 1000 ml. Further, the nutritional composition of the present invention can be administered in a larger amount at a time than the conventional nutritional composition for suppressing hyperglycemia, which has a higher effect of suppressing postprandial hyperglycemia. In this case, the package type of the disposable type can be used simply and hygienically, and since it is advantageous in terms of the cost of transporting the package material in a large capacity, it can be provided to consumers in a product that can be stored in a cheap environment. In this case, the charge per unit is preferably from 300 to 600 ml, more preferably from 300 to 400 ml. In the case of an elderly person or a child, the stomach volume is also small. This condition is preferably preferably 80 to 400 ml, more preferably 100 to 300 ml. As the container for accommodating the nutritional composition of the present invention, it is preferably a container which is easy to open, and is preferably self-contained. A container described in JP-A-2003-327259, and the like. On the other hand, when the nutrient composition of the present invention is intended to contain various food materials, there is a possibility that a part thereof causes oxidation or decomposition at the time of production or storage. In particular, oils and fats are liable to cause deterioration. Among them, a large amount of highly unsaturated fatty acids such as fish oil or perilla oil and almond oil are more likely to be oxidized, and -15-200942181 causes unpleasant odor and taste deterioration. Further, it has been suggested that when a fat containing a peroxide is ingested, "the oxidative stress is applied to the living body, and the promotion of aging or carcinogenesis" is one of the lifestyle diseases. Such oxidation or decomposition can be suppressed as much as possible by (i) the method of manufacture or (ii) the form of the package. Specifically, it can be achieved by: (i) suppressing the entrapment of air in the conditioning/dispensing solution during production or under shading; after the formulation, removing air by means of a degassing device or by charging an inert gas; Avoid the necessary heating above, and keep it as low as possible before the sterilization treatment after the end of the preparation; the charging is carried out in an inert gas atmosphere or after being replaced with an inert gas, and the residual gas is reduced to seal it; (ii) A gas barrier film, for example, a vapor deposition film or a deoxidizing packaging material made of aluminum, aluminum oxide, cerium oxide or the like, and further encapsulated in a package form of a deoxidizer such as AGEGESS, and further used as an ultraviolet absorbing ink or a special gas barrier ink. The surface-printed packaging material' is further subjected to gas replacement or degassing treatment after being packaged in the outer packaging material. In this way, it is also possible to suppress a decrease in the residual ratio of nutrients such as vitamin C, retinol or vitamin E due to oxidation of fats and oils, deterioration of flavor, and the like, and it is more preferable in the present product. [Examples] Hereinafter, the present invention will be described in detail by way of examples, but the invention should not be construed as limited. Example 1 The raw materials were metered in the proportions shown in Table 1, and the blending was carried out at the loading of 2,000 -16 - 200942181 kcal / 2,000 ml. 765 grams of blended water was metered into a 3 liter stainless steel drum and heated to 70-80 °C in a hot water bath. The mixture was mixed with dextrin, insoluble dietary fiber, mineral-containing yeast, biotin yeast, zinc gluconate, copper gluconate, sodium ferrous citrate and dispersed. Then, a liquid obtained by mixing and dissolving edible fats and oils, medium-chain fatty acid triglyceride, carotenoid suspension, vitamin E oil and emulsifier at 70 to 80 ° C was added. Next, milk protein, isomaltulose, 0 water-soluble dietary fiber was added thereto and dissolved. In addition, 180 grams of warm water (30~40 °C) is injected into the stainless steel container, and citric acid, calcium hydroxide, trisodium citrate, potassium carbonate, magnesium chloride, calcium glycerate, sodium amide are dissolved in sequence. The solution was placed in a pre-conditioned solution in a 3 liter stainless steel container and mixed. Next, *, isoleucine, sodium erythorbate, and vitamins are added thereto, and dispersed and dissolved, followed by addition of a fragrance. Finally, sodium ascorbate is added and dissolved and mixed. After mixing the water to make the total amount 2,000 ml, the mixture was stirred until it was homogeneous. The solution was emulsified by a high pressure homogenizer (homogeneous pressure: 7 OMPa). It was filled in a standing pouch (packaging material composition: vapor-deposited PET/Ny/CPP), and each weight was 200 ml (214 g), and subjected to autoclaving at 124 t, and it was measured after 5 days. The viscosity of the liquid was 6.4 mPa.s (24 ° C). Further, it was further filled with a 117 ml (125 g) bag by sterile filling. Among them, Ny and CPP which are constituent materials of the transparent standing pouch are short for nylon and non-stretched polypropylene (the same applies hereinafter). Emulsification in any of these packaging forms is also long-term stability. In addition, the camp -17- 200942181 is a nutritionally balanced person with long-term continuous intake. Among them, the number of carbon atoms constituting the fatty acid residue using the medium chain fatty acid triglyceride is 6 to 12. In addition, the ratio of the ω6 fatty acid/ω3 fatty acid was adjusted to 2.7. The content of isomaltulose in the saccharide was 6.4% by mass (39.2/239.2). The amount of isomaltulose in the product i〇〇kCal of the present invention was 1.96 g. Further, the amount of free isoleucine in the product i〇〇kcai of the present invention is

质量.5g, the mass ratio of free isoleucine/isomaltulose was 1/3.9 (10/39.2).

The tackifier was appropriately added to the nutritional composition of the present invention thus produced, and the viscosity was measured using a rotary viscometer (BH-80, Toki Sang), and it was confirmed that it was adjusted to 3 50 to 20, OOO mPa. s. Stabilized high viscosity composition (23 ° C). Further, the solution of the present invention is spray-dried, and by granulating it, the powder and the granules can be stably produced. Further, a moderately added agar or a commercially available jelly-prepared food (for example, a HERUSHU (registered trademark) jelly composition) in the heated product of the present invention can be prepared into a gel form after being dissolved and cooled. . -18- 200942181

Table 1 Formulation composition of Example 1 (2,000 kcal / 2,000 ml) Raw material name usage unit milk protein 82.6 g dextrin 200.0 g isomaltulose 39.2 g insoluble dietary fiber 8.0 g water soluble dietary fiber 27.0 g edible fat 42.7 g Medium chain fatty acid triglyceride 22.6 grams emulsifier 12.5 grams citric acid 7.5 grams of hydroxide 15 1.4 grams of trisodium citrate 5.4 grams of potassium carbonate 5.6 grams of magnesium chloride 4.8 grams of calcium glycerophosphate 3.2 grams of sodium glutamate 6.0 grams of isoleucine 10.0 g sodium ascorbate 1.29 g sodium isosodium sulphate 0.54 g sodium ferrous citrate 180.0 mg zinc gluconate 230.0 mg copper gluconate 14.0 mg yeast containing selenium 80.0 mg yeast containing molybdenum 12.0 mg yeast containing manganese 180.0 mg containing chromium Yeast 52.0 mg Iodine-containing yeast 22.0 mg Biotin Yeast 244.0 mg Vitamin E oil 167.9 mg Cold-carotene suspension 26.4 mg Fragrance 3 1.6 g Multivitamin Vitamin A palmitate 36.0 mg Vitamin B1 hydrochloride 27.1 mg Nuclear yellow Sodium phosphate phosphate 10. 2 mg of vitamin B6 hydrochloride 17.72 mg of vitamin Β 12 (0.1% water-soluble powder) 15.0 mg of vitamin D 3 1.8 mg of niacin guanamine 49.0 mg of folic acid (vitamin Μ) 1. 7 mg of calcium pantothenate 28.8 mg of vitamin Κ 2 ( 0·2% emulsified powder) 22.1 mg-19- 200942181 Example 2 The raw material compounding ratio shown in Table 2 was measured and the formulation at the time of loading of 1,000 g (2,000 kcal) was carried out. 320 g of the formulated water was metered into a 2 liter stainless steel drum and heated to 7 〇 to 80 ° C in a hot water bath. Next, in TK ROBOMIX (PRIMIX), the condition was tempered at a high speed of 3 OOO rpm, based on trehalose, sodium ferrous citrate, zinc gluconate, copper gluconate, potassium citrate, potassium chloride, phosphoric acid. The order of potassium and sodium gluconate is mixed and dissolved. Then, the liquid is mixed with a medium-chain fatty acid triglyceride, a carotene suspension, a vitamin E oil, and an emulsifier at 70 to 80 ° C to dissolve the liquid. Subsequently, according to dextrin, milk protein, insoluble dietary fiber, sodium citrate, leucine, yeast containing various minerals, biotin yeast, and spices, the ingredients are put into and mixed to form a uniform dissolved and dispersed solution, and then slowly input. A liquid obtained by dissolving water-soluble dietary fiber, magnesium sulfate, magnesium chloride, and calcium lactate in 120 ml of formulated water. Subsequently, synthetic vitamins, sodium ascorbate, sodium erythorbate were added and dispersed. While measuring the weights, water was added to 1, gram, and mixed until it became homogeneous. This was carried out in an upright belt (bag film composition: PET/Al/Ny/CPP) filled with an additional nozzle per 100 ml, and autoclaved at 125 °C. Its specific gravity was 1.18, and the caloric concentration of the solution was 2.0 kcal/g (2.4 kcal/ml). The sample was stored at 25 ° C, and the next day after the sterilization treatment, it was measured by a rotary viscometer (BH-80, Toki Sangyo Co., Ltd.) under the condition of No. 3 rotor and 12 rpm, and was about 4,000 mPa·s ( 2 5 °C). Emulsification under long-term storage is also stable for a long time Adding water to the liquid can be adjusted to a homogeneous nutrient composition of 500 mPa · s (25 ° C), and can also be added -20- 200942181

The commercially available tackifier was adjusted to a homogenous high viscosity solution of 7,000 mPa.s (25 °C). Further, a moderately added agar or a commercially available jelly-prepared food (for example, a HERUSHU (registered trademark) jelly composition) in the heated product of the present invention may be prepared into a gel after being dissolved and cooled. form. Further, the solution of the present invention is spray-dried, and by granulating it, the powder and the granules can be stably produced. The number of carbon atoms constituting the fatty acid residue in which the medium chain fatty acid triglyceride is used is 8 to 1 Å. Further, the ω6-based fatty acid "3 series fatty acid ratio is 1.5. The trehalose content in the saccharide is 9.5% by mass ( 18.3/192.8), and the amount of trehalose in the present invention 100 kcal is 0.92 g. Further, the present invention 100 kcal The amount of free leucine is 〇-27g, and the mass ratio of free leucine to trehalose is 1/3.4 (5.40/18.3) 200942181 Table 2 Formulation of Example 2 (2,000kcal/l,000g) Usage unit milk protein 99.0 g dextrin 174.5 g trehalose 18.3 g insoluble dietary fiber 5.0 g water soluble dietary fiber 25.0 g edible fat 58.0 g medium chain fatty acid triglyceride 13.7 g emulsifier 5.3 g calcium lactate 3.30 g potassium citrate 3.10 grams of potassium chloride 0.60 grams of potassium phosphate 3.30 grams of magnesium chloride 2.60 grams of magnesium sulfate 3.80 grams of sodium gluconate 19.1 grams of sodium citrate 4.50 grams of leucine 5.40 grams of sodium ascorbate 1.30 grams of sodium erythorbate 2.90 grams of sodium ferrous citrate 180.0 Mg of zinc gluconate 2 3 0.0 mg of copper gluconate 14.0 mg of yeast containing selenium 80.0 mg of yeast containing molybdenum 12.0 mg containing manganese Yeast 180.0 mg Chromium-containing yeast 52.0 mg Iodine-containing yeast 22.0 mg Biotin yeast 244.0 mg Perfume 1.0 G-vitamin E oil 167.9 mg Beta-carotene suspension 26.4 mg Vitamin Α palmitate 36.0 mg Vitamin B 1 hydrochloride 27.1 Mg riboflavin sodium phosphate 10.2 mg Synthetic vitamin B6 hydrochloride 1 7.72 mg of vitamin Β 12 (0·1% water-soluble powder) 15.0 mg of vitamin D 3 1.8 mg of his nicotinic acid guanamine 49.0 mg of 'folate ( Vitamin Μ) 1.7 mg calcium pantothenate 28.8 mg vitamin Κ 2 (0·2% emulsified powder) 22.1 mg-22- 200942181 Example 3 Ο

The raw materials were metered in the proportions as shown in Table 3, and 2,000 kcal / 2,000 ml of the nutritional composition was prepared in the same manner as in Example 1. It was filled in a transparent standing pouch so that each weight was 200 g. Autoclaved sterilization at 124 °C. The viscosity at this time was 6.0 mPa.s (24 ° C). The emulsification is long-term stability. Further, the nutritional composition is excellent in nutritional balance and can be continuously ingested for a long time. The number of carbon atoms constituting the fatty acid residue in which the medium chain fatty acid triglyceride is used is 6 to 12. Further, the ratio of the omega 6 fatty acid / 03 fatty acid was 4.0. The content of isomaltulose in the saccharide was 16.4% by mass (39.2/239.2), and the amount of isomaltulose in the 100 kcal of the present invention was 1.96 g. Further, the amount of free isoleucine in the 100 kcal of the present invention is 〇.5 g, and the mass ratio of free isoleucine/isomaltulose is 1/3.9 (10/3 9.2). Further, the free arginine in lOOkcal was 1.5 g. The tackifier is appropriately added to the nutritional composition of the present invention thus produced, and after measuring the viscosity using a rotary viscometer (BH-80, Toki Sang), it is 3 50 to 20,000 mPa·s, and it can be confirmed that it can be adjusted to stability. High viscosity composition (23 °C). Further, a moderately added agar or a commercially available jelly-prepared food (for example, a HERUSHU (registered trademark) jelly composition) in the heated product of the present invention may be prepared into a gel after being dissolved and cooled. Shape. Further, the solution of the present invention is spray-dried, and by granulating it, the powder and the granules can be stably produced. -23- 200942181 Table 3 Formulation composition of Example 3 (2,000kcal/2,000ml) Raw material name Usage unit Milk protein 82.6 g L-arginine L-valerate 2.8 g dextrin 200.0 g isomaltulose 39.2 g insoluble dietary fiber 8.0 g water soluble dietary fiber 27.0 g edible fat 42.7 g medium chain fatty acid triglyceride 22.6 g emulsifier 12.5 g citric acid 7.5 g calcium hydroxide 1.4 g trisodium citrate 5.4 g potassium carbonate 5.6 g magnesium chloride 4.8 g of calcium glycerophosphate 3.2 g of sodium citrate 4.4 g of isoleucine 10.0 g of sodium ascorbate 1.29 g of sodium erythorbate 0.54 g of sodium citrate 180.0 mg of zinc gluconate 23 0.0 mg of copper gluconate 14.0 mg containing selenium Yeast 80.0 mg Molybdenum-containing yeast 12.0 mg Manganese-containing yeast 180.0 mg Chromium-containing yeast 52.0 mg Iodine-containing yeast 22.0 mg Biotin yeast 244.0 mg Vitamin E oil 167.9 mg yS-carotene suspension 26.4 mg flavor 1.6 g of vitamins A palmitate 36.0 mg of vitamin B1 hydrochloride 2 7.1 mg of riboflavin phosphate 10.2 mg of vitamin B6 hydrochloride 17.72 mg of vitamin B1 2 (0.1% water-soluble powder) 15.0 mg of vitamin D3 1.8 mg of nicotinic acid guanamine 49.0 mg of mouth P folic acid (vitamin M ) 1.7 mg calcium pantothenate 28.8 mg vitamin Κ 2 (0.2% emulsified powder) 22.1 mg-24- 200942181 Example 4

The raw materials were measured in the blending ratio shown in Table 4, and a real machine test at the time of loading of 3000 L (lkcal/lml) was carried out. Feed 1 164kg (70~80 °C) of warm water in the No. 1 bucket, add dextrin, insoluble food fiber, mineral-containing yeast, sodium ferrous citrate while stirring. Next, a liquid obtained by mixing and dissolving edible fats and oils, medium-chain fatty acid triglyceride, 8-carotene suspension, vitamin E oil and emulsifier at 70 to 80 °C is added. Next, milk protein, isomaltulose, and water-soluble dietary fiber are put therein and dissolved. Add 135kg of warm water (30~40°C) to another barrel, and dissolve citric acid, calcium hydroxide, trisodium citrate, potassium carbonate, magnesium chloride, calcium glycerate, sodium amide, and This solution was added to a pre-conditioned No. 1 barrel solution. This was mixed and the operation was repeated twice. Next, isoleucine, sodium erythorbate, and vitamins are added thereto, and dispersed and dissolved, and then folic acid and flavor are added. After the liquid was degassed (about 20 cmHg), it was treated with a high pressure homogenizer at an emulsification pressure of 98 MPa, and the liquid temperature was made 1 (TC or less) by a plate cooler. After storage in a liquid storage tank, sodium ascorbate was added. And dissolve it, and mix the water to make the total amount to 3,000 L, and stir until it becomes a uniform liquid. Fill it with a transparent film bag with additional nozzle (bag film composition: PET7 steamed PET/Ny/CPP In each case, the weight is 400 ml, and after the filling, the residual gas portion is sealed to 15 ml or less with a degassing rod, and then sealed with a heat seal, and then subjected to autoclaving at 124 ° C. After 8 days, the measurement is carried out. The viscosity of the liquid is 6.3 mPa · s (24 ° C). -25- 200942181 In addition, the amount of free isoleucine in the 100 kcal of the present invention is 0.5 g, and the mass of free isoleic acid/isomaltulose The ratio is 1/3.9 ( 15.0/58.8). 200942181 Ο % Table 4 Example 4 compounding composition 3000L loading _„_ Raw material name usage unit milk protein ~ 123.9 kg S" fine 3 00.0 kg isomaltulose- 58.8 kg of insoluble dietary fiber 12.0 Pound water soluble dietary fiber 40.5 kg edible fat 97.88 kg medium money 1 fatty acid diglyceride 33.9 kg emulsifier 18.75 kg citric acid 11.3 kg calcium hydroxide 2.1 kg trisodium citrate 8.1 kg mmm 8.4 kg magnesium chloride 7.2 kg glycerol phosphate bell - 4.8 kg sodium citrate 9.0 kg isoleucine '15.0 kg sodium ascorbate 1.93 kg sodium erythorbate 0.8 1 kg sodium ferrous citrate 0.270 kg zinc gluconate 0.345 kg copper gluconate 0.02 1 kg yeast containing selenium 0.1200 Kiln yeast containing molybdenum 0.0180 kg yeast containing manganese 0.2700 kg yeast containing chromium 0.0780 "kg iodine-containing yeast 0.0330 kg biotin yeast 0.3660 kg vitamin E oil 0.2190 kg 厶-carotene 1% water-soluble powder 1.190 kg scent 2.4 Kg Vitamin A Palmitate 54.00 Gram Vitamin B1 Hydrochloride 33.90 g Synthetic Sodium Flavin Phosphate 15.30 Gram Vitamin B6 Hydrochloride 26.58 Kevivitamin B12 (0.1% Water Soluble Powder) 19.50 Gram Vitamin D3 4.05 g Nicotinic acid decylamine 86.40 g of folic acid (vitamin M) 2.34 g of calcium pantothenate 43.20 g of vitamin K2 (0.2% emulsified powder) 39.00 g -27- 200942181 Test Example 1 The test piece obtained in Example 4 was carried out in the room. Temperature (around 25 °C) Long-term stability test stored for 6 months. The physical properties were measured and evaluated for the test pieces at the start of the test and at room temperature for 6 months. • Particle size distribution (midium particle size) Laser scattering type particle size distribution measuring device (LS 1 3 320 (trade name), manufactured by Beckman Kodak Company), using PIDS (polarized differential scattering) component, in liquid (suspended) Liquid part): 1.32, sample: physical part 1.45, virtual part 0 conditional resolution rate.

• The pH was measured by a pH meter (Model HM-25R (trade name), manufactured by TOA DKK Co., Ltd.). • Viscosity was measured by a rotary viscometer (BH-80 (trade name), manufactured by Toki Sangyo Co., Ltd.) using a No. 10 rotor at 60 rpm. • Functional evaluation For the flavor, aroma, and tongue touch, the test pieces that were just started to be stored were compared as standard samples. In comparison with the standard sample, it is appropriate to judge the situation that is not inferior. • 5 g sample was taken from the vial for color difference measurement, and measured using a spectroscopic color meter (SE- 2 000 (trade name), manufactured by Nippon Denshoku Industries Co., Ltd.). • Appearance-28 - 200942181 Observed with emulsified state The state of the visual appearance such as the formation of a milky or insoluble salt and a significant change in color tone. • In the tube, a tube (JMS nutrition kit (trade name), manufactured by JMS) and a 5Fr tube (SURFI FITTING TUBE (product name), manufactured by TERUMO) are connected to the nozzle of the sample, and The contents were allowed to drip naturally, and the amount dropped every 15 minutes was measured. Continuously drip hi until there is no liquid in the bag, and the average dropping flow rate per unit time is obtained as the fluidity in the tube. • Acid resistance Take 100 ml of the sample in a beaker and slowly add a pre-conditioned 2% hydrochloric acid solution while stirring with a stirrer. After 2 minutes, observe the traits, " and measure the pH. At this time, the pH of the condensed milk-like floats after tens of or more was confirmed (the aggregate produced after the addition of the hydrochloric acid solution did not disappear) was measured. Comparative Example 1 The same storage test as in Test Example 1 was carried out for the purchased mobile food (MEDIEFF (registered trademark) bag, manufactured by Ajinomoto Co., Ltd.), and the physical properties were measured and evaluated. The results of the measurements obtained are shown in Table 5. Even in the particle size distribution 'pH' viscosity, chromatic aberration, no significant change was observed after 6 months of storage, and the product was shown to have sufficient stability for at least 6 months. In the evaluation of the functionality, the change over time was also small, and the preferred form of oral ingestion was maintained. Also -29- 200942181 The invention has good viscosity and good fluidity, so various nutrient tubes or tubes can also be used, especially in the form of small inner diameter and long length. In addition, since the acid resistance is also excellent, it is difficult to cause the flow food to coagulate when the gastric acid is reversely flowed to the catheter, and the proliferation of the bacteria which is reported to be the cause of coagulation does not occur (Non-Patent Document 3: Surgical and Metabolic, Nutrition, Japanese Surgical Metabolism) The Journal of the Nutrition Society, pp73 '42 (3), 2008), even if it is used at the same time or before and after the use of acidic agents, it is claimed that it will not cause tube blockage. From the above, the present invention also has an excellent form when used in the management of nutrients. Table 5 Storage stability test results of Example 1 and Comparative Example 1 Example 1 Comparative Example 1 The measurement unit was initially subjected to 6 months in the first 6 months. Diameter β m 0.106 0.103 0.103 0.107 pH 6.12 6.06 6.50 6.40 Viscosity mPa · s 6.30 6.50 9.60 10.34 Functionality Suitable and suitable Suitable color difference ΔΕ* 46.92 49.36 42.11 48.52 Appearance - No problem No problem No problem No problem Tube fluidity mL/h 139 146 89 84 Acid resistance (pH) 5.0 - 5.9 Example 5 The raw materials were metered in the proportions shown in Table 6, and the blending was carried out at 4500 kcal/4,500 ml. Into a 5-liter stainless steel bucket, weigh 2000g of blended water and warm it to 70~8〇ac in a hot water bath. Into the dextrin, insoluble dietary fiber, milk protein, isomaltulose, water-soluble dietary fiber, mineral-containing yeast, biotin yeast, glucose-30- 200942181 zinc acid, copper gluconate, citric acid Sodium ferrous, isoleucine, sodium amide and dispersed. Next, a liquid obtained by mixing and dissolving edible fats and oils, medium-chain fatty acid triglyceride, phyto-carotene suspension, vitamin E oil, and emulsifier at 70 to 80 t is introduced.

In addition, 300 grams of warm water (30 ~ 40 ° 〇) is placed in a stainless steel container, and citric acid, calcium hydroxide, trisodium citrate, potassium carbonate, magnesium chloride are sequentially dissolved, and the solution is put into 5 liters of stainless steel. The pre-conditioned solution in the container is mixed. Next, tricalcium phosphate, a synthetic vitamin, and dissolved in a dispersion are added thereto, and a fragrance is added. Finally, sodium erythorbate, sodium ascorbate is added and dissolved and mixed. The amount of water was adjusted so that the total amount became 4,500 ml, and then the mixture was stirred until it became a homogeneous solution. The solution was emulsified by a high pressure homogenizer (homogeneous pressure: 70 MPa). This was filled in a transparent film bag (bag film structure: PET/vaporized PET/Ny/CPP) with an additional nozzle to make each volume 300 ml, and subjected to autoclaving sterilization at 124 °C. The viscosity of the nutrient is T.OmPa.s^^C), and the storage stability is excellent over time, especially when stored at high temperature (40~6(TC) is also rarely milky, and it is also considered that it is not derived from insoluble phosphoric acid. The production of calcium precipitates. The flavor and the fluidity in the tube are also good. In addition, the amount of free isoleucine in the product l〇〇k cal of the present invention is 〇·5 g 'free isoleucine/iso malt The mass ratio of ketose was 1/3.9 (22.5/88.2). -31 - 200942181 Table 6 Formulation of Example 5 (4,500kCal/4,500ml) Raw material name Usage unit Milk protein 185.9 gdextrin 450.0 g of malt Ketoose 88.2 g Insoluble dietary fiber 18.0 g Water-soluble dietary fiber 60.8 g Edible fat 96.2 g Medium chain fatty acid triglyceride 50.9 g Emulsifier 28.1 g Citric acid 12.6 g Calcium hydroxide 1.8 g Trisodium citrate 11.7 g Potassium carbonate 12.6 Gram magnesium chloride 10.8 g Tricalcium phosphate 5.4 Grams sodium citrate 13.5 g Isoleucine 22.5 g Sodium ascorbate 3.29 Sodium erythorbate 1.96 g Sodium citrate 405.0 mg Zinc gluconate 5 17.5 mg Copper citrate 3 1.5 mg Yeast containing selenium 180.0 mg Yeast containing molybdenum 27.0 mg Yeast containing manganese 405.0 mg Yeast containing chromium 117.0 mg Yeast containing iodine 49.5 mg Biotin yeast 549.0 mg Vitamin E oil 328.5 mg Call-carotene Suspension 74.3 mg of fragrance 3.2 g of vitamin A palmitate 58.5 mg of vitamin B1 hydrochloride 67.5 mg of sodium riboflavin phosphate. 23.0 mg of vitamin B6 hydrochloride 40.1 mg of vitamin Β 12 (0·1% water soluble powder) 84.2 mg of vitamin D 3 3.6 mg of his nicotinic acid decylamine 94.5 mg of phlegonic acid (vitamin Μ) 4.1 mg of calcium pantothenate 64.8 mg of vitamin Κ 2 (0.2% emulsified powder) 58.5 -^4* -4 · mg-32- 200942181 Efficacy Evaluation of the Nutritional Composition of the Invention Product Experiment 1 (Reference Example: Efficacy when only isomaltulose was used) 0 % GK mice (7-week-old males, 7-week-old males) used for diabetic mice with abnormal sugar tolerance SLC (shares)) Experiments. GK rats were fasted for 18 hours and administered orally with glycosides (12 g / lOO) One part of kcal ) was replaced with the nutritional compositions A, B, and C shown in Table 7 of gram, 4.4 g, and 8-9 g/lOOkcal of isomaltulose (the nutrient composition basis of Example 1 in which no formulation was made. Free isoleucine) (12 kcal/kg B.W.), and blood glucose was measured (measurement machine: Fuji DRYCHEM 5500, manufactured by Fujifilm Co., Ltd.). As a result, the nutritional composition C was significantly inhibited from the nutritional composition A after 15, 30, and 60 minutes of administration of the nutritional composition (15, 30 minutes: p < 0.01 ' 60 minutes: ρ <;0·05, parametric D unnet type multi-check, Figure 1). However, the nutrient composition Β compared with the nutrient composition A does not inhibit the rise of blood sugar ( (Fig. 1) ° From the result, only isomaltulose is used, and it is not used with free isoleucinate. When the amount of isomaltulose in an amount of about 70% by mass or more of the saccharide is not used, it is judged that the effect of suppressing the increase in blood sugar 异 of isomaltulose is not sufficiently exhibited. -33- 200942181 Table 7 Composition of nutritional composition A, B, C (2,000 kcal / 2,000 ml) Raw material name Unit composition A Composition B Composition C Milk protein gram 92.6 Dextrin gram 239.0 150.4 6 1.6 Isomalt Ketoose gram 0 88.6 177.4 Insoluble food fiber gram 8.0 Water-soluble dietary fiber gram 27.0 Edible oil gram 42.7 Medium chain fatty acid triglyceride gram 22.6 Emulsifier gram 12.5 Citric acid gram 7.5 Calcium hydroxide gram 1.4 Trisodium citrate 5.4 Carbonic acid Potassium gram 5.6 Magnesium chloride 4.8 Calcium phosphate gram 3.2 Sodium amide sodium 6.0 Isoleucine gram sodium ascorbate 1.28 Sodium oxalate 0.54 Sodium citrate gram 180.0 Zinc gluconate mg 230.0 Copper gluconate mg 14.0 Selenium-containing yeast mg 80.0 Molybdenum-containing yeast mg 12.0 Manganese-containing yeast mg 180.0 Chromium-containing yeast mg 52.0 Iodine-containing yeast mg 22.0 Biotin yeast mg 244.0 Vitamin E oil mg 167.9 Cold-carotene suspension mg 26.4 Fragrance mg 1.6 Vitamin A Palmitate mg 36.0 Vitamins B1 hydrochloride mg 27.1 riboflavin sodium mg 10.2 Vitamin B6 hydrochloride mg 17.72 Vitamin B12 (0_l% water soluble powder) mg 15.0 Vitamin D3 mg 1.8 Nicotinamide mg 49.0 Folic acid (vitamin M) mg 1.7 Calcium pantothenate mg 28.8 Vitamin K2 (0 · 2 % emulsified powder) mg 22.1 -34- 200942181 Experiment 2 The GK mouse of a diabetic model mouse exhibiting an anti-sugar tolerance abnormality is used for the blood glucose increase inhibitor of the present invention (at 7 weeks of age) The male 'Sakamoto SLC (share)) was tested. The nutritional composition of the present invention prepared in Example 1 and the nutritional composition A (12 kcal/kg B.W.) of unisolated free isoleucine and isomaltulose were administered to the rats fasted for 18 hours, respectively. And blood glucose 测定 was measured (measurement machine: Fuji DRYCHEM 5500, Fujifilm (share) system). As shown in Fig. 2, the present invention can intentionally suppress the increase in blood glucose sputum after 60 and 120 minutes of administration of the nutritional composition as compared with the nutritional composition A (p < 0.05, t-test, Fig. 2). From this result, it was judged that the use of free isoleucine and isomaltulose could exert an extremely strong effect of suppressing blood sugar rise. The effect of suppressing the increase in the blood sugar level of isomaltulose is not sufficiently exerted when the isomaltulose is not prepared in a ratio of about 70% by mass or more of the saccharide, but 0.5 g of free isoleucine per 100 kcal is used. At the time, the amount of isomaltulose can be reduced to 16% by mass of the saccharide. Experimental Example 3 The inventive product prepared in Example 2 and the nutritional composition D were respectively administered into the stomach through a gastric fistula of GK mice (14-year-old male rats, Japanese SLC (stock)) (l2 kcal/kg B.W. And the measurement of blood glucose 値 (measurement machine: Fuji DRYCHEM 5500, Fujifilm Co., Ltd.). The nutrient composition D was prepared according to Table 8, and was produced as in Example 2, and the calorie concentration of the solution was 2.4 kcal/ml', and the physical property represented by the viscosity was the same as in Example 2. In the case of fats and oils, the ratio of use of edible fats and oils is adjusted so that the ratio of the omega 6 fatty acid / α > 3 fatty acids is 1.5. The carbon number of the fatty acid residue constituting the medium chain fatty acid triglyceride is 6 to 12. The ratio of the medium chain fatty acid to the total fat was 18% by weight. The saccharide does not contain trehalose, and it does not contain free leucine. As a result of the experiment, the product of the present invention can intentionally suppress the increase in blood glucose 15 after 15, 30, and 60 minutes of administration compared with the nutritional composition D (ρ < 0.05, t test, Fig. 3). The comparative nutrient composition D adjusted the calorie concentration to a high calorie of 2.4 kcal/ml (specific gravity 1.18), and when it was administered to a diabetic model mouse, hyperglycemia was induced. However, the composition of Example 2 can suppress the increase in blood glucose even when the calorie concentration is 2.4 kcal/ml (specific gravity 1.18) (Fig. 3). In elderly patients with diabetes, they are unable to take up their own nutrition. Most patients have a nutritional composition that is directly administered to the stomach by stomach cramps. Because the stomach capacity of the elderly is small, the nutrient composition used is preferably small in size and high in calorie concentration. However, when the administration speed is the same, increasing the calorie concentration is likely to cause a certain degree of high blood sugar. . However, as shown by the results, the present invention of a high calorie concentration of 2.4 kcal/ml confirmed that it did not cause hyperglycemia. -36- 200942181

Table 8 Composition of nutritional composition D (2,000kcal/l,000g) Raw material name Usage unit Milk protein 1 04.4 grams of dextrin 192.8 grams of trehalose - grams of insoluble dietary fiber 5.0 grams of water soluble dietary fiber 25.0 grams of edible fat 58.0 grams Medium chain fatty acid triglyceride 13.7 g emulsifier 5.3 g calcium lactate 3.30 g potassium citrate 3.10 g potassium chloride 0.60 g potassium phosphate 3.30 g magnesium chloride 2.60 g sulfuric acid money 3.80 g sodium gluconate 19.1 glysinate 4.50 g Leucine sodium gram ascorbate 1.30 g sodium isoascorbate 2.90 g sodium citrate 180.0 mg zinc gluconate 230.0 mg copper gluconate 14.0 mg yeast containing selenium 80.0 mg yeast containing molybdenum 12.0 mg yeast containing manganese 180.0 mg Chromium-containing yeast 52.0 mg Iodine-containing yeast 22.0 mg Biotin yeast 244.0 mg Perfume 1.0 mg Vitamin E oil 167.9 mg Dot-carotene suspension 26.4 mg Synthetic Vitalin Vitamin A palmitate 36.0 mg Vitamin B 1 Hydrochloric acid Salt 27.1 mg nuclear yellow Sodium phosphate 10.2 mg Vitamin B6 hydrochloride 17.72 mg Vitamin B1 2 (0.1% water soluble powder) 15.0 mg Vitamin D3 1.8 mg Nicotinamide 49.0 mg Folic acid (vitamin M) 1.7 mg Calcium pantothenate 28.8 mg Vitamin K2 (0.2 % emulsified powder) 22.1 mg-37- 200942181 Experiment 4 Verification of the hemoglobin Ale (HbAlc) of the present invention using a ZDF mouse (10-week old male, Charles River, Japan) for the diabetic model of abnormal glucose tolerance ) The rising inhibitory effect. HbAlc is an indicator of blood glucose sputum in the past month or so. In addition, in the ZDF mouse, HbAlc gradually rises from the age of 10 weeks as the disease progresses, and it is a model showing the state of the process of deterioration of human diabetes. The mice were divided into two groups in such a way that the average enthalpy of HbAlc was equalized, and the nutrient composition E containing 0.5 g of free isoleucine and 2.0 g of isomaltulose was taken freely per 100 kcal of each nutrient composition, respectively. The nutrient composition F of free isoleucine and isomaltulose was formulated, and HbAlc was compared after 4 weeks (nutrition composition composition: Table 9, measuring machine: DCA2000 system, SIEMENS MEDICAL SOLUTIONS · DIAGNOSTICS (share) system) . Nutrition Compositions E and F are formulated with vitamins and minerals (AIN-93G Vitamin Blend and AIN-93G Mineral Blend, manufactured by ORIENTAL Yeast Industries). As a result, the nutrient composition E was judged to be more effective in suppressing the increase rate of HbAlc than the nutrient composition F, and each nutrient composition 100 kcal was combined with 0.5 g of free isoleucine and 2.0 g of isomaltulose (free isoprene). Amino acid/isomaltulose has a mass ratio of 1/4, and the content of isomaltulose in the saccharide is 12% by mass), which is useful for the control of long-term blood sugar, and proves to be inhibited under conditions of free oral ingestion. Blood sugar rise (p<0.05, t-test, Figure 4 -38- 200942181 Table 9 Composition of nutrient composition E, F (1 00kcal/27g) Raw material name Unit composition E Composition F Milk protein 4.9 5.4 Isoleucine Acid gram 0.5 - corn starch gram 15 17 isomaltulose gram 2.0 - insoluble food fiber gram 1.3 edible oil (medium chain fatty acid triglyceride% w/w) gram 1.9 (30) vitamin AIN-93G vitamin mixed mineral AIN-93G Mineral Mixing Experiment 5 The anti-hypertensive effect of HbAlc' of the present invention was verified by using Streptozocin (STZ)-induced diabetic mice with abnormal sugar tolerance. STZ-induced diabetic mice HbAlc rises after administration of STZ and shows a model close to the state of progression of human diabetes. SD rats (7-week-old male, Sakamoto ^ Charles River) were administered intraperitoneally to STZ 60 mg/kg B. .W., a diabetic model rat was prepared. After 8 days of STZ administration, the mice were divided into two groups in such a manner that the average enthalpy of HbAlc was equalized, and the powdered nutrient composition having the composition of Example 1 was freely ingested and unmixed, respectively. A powdery nutrient composition of the nutritional composition A of free isoleucine and isomaltulose was measured, and HbAlc was measured after 6 weeks (measurement apparatus: DCA2000 system, manufactured by SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS Co., Ltd.). The blending composition of the nutritional composition of the present invention (unmixed water used) and the nutritional composition A shown in Fig. 1 was prepared by mixing a raw material using a universal mixing mixer (DALTON Co., Ltd. - 39-200942181). The nutritional composition of the present invention determines that the increase in Hb A 1 c can be remarkably suppressed as compared with the nutritional composition A. Moreover, it is proved that the nutritional composition of the present invention is even in powder form for blood sugar. Control is also useful (p < 0.01, t test, Figure 5). In the case of diabetic patients and sugar tolerance, the inhibition of rapid increase in blood glucose sputum during nutritional intake is the use of insulin injection or oral hypoglycemic agents. Insulin or oral hypoglycemic The drug is strong in inhibiting the rise of blood sugar, but it is accompanied by side effects such as hypoglycemia or gastrointestinal damage, edema, and anemia. In addition, more than half of the patients who underwent insulin therapy also reported that they had acupuncture pain (Non-Patent Document 4: Jialai Haoping, Practice, 22 (3), 240, 2005). Insulin injection caused great mental stress. . According to the present invention, since hyperglycemia during administration can be suppressed in the case of long-term ingestion, the administration amount of insulin and oral hypoglycemic agents can be reduced, and the side effects of the drug and the pressure reduction of acupuncture can be contributed. Experiment 6 GK mice (Sakamoto SLC (strand)) which exhibited a diabetic model rat with abnormal glucose tolerance were placed in a low-nutrient state, and the nutritional effects of the composition of the present invention were verified. That is, 11-week-old GK mice were fed a protein-free mouse for 21 days to prepare a model rat with a low nutritional status which was abnormal in sugar tolerance. The mice were divided into two groups according to the average of the body weight and the fasting blood glucose level. The laparotomy was performed through the stomach sputum, and the pump was used in the stomach. The first day was 20kcal/18. Hours/only, the first to the second day is -40- 200942181

45kcal/18 hours/only, 65kcal/18 hours/only on the 2nd to 7th days, 71kcal/20 hours/day after the 7th day', the liquid of Example 1 was administered to a group within 1 day. In the case of the composition of the present invention, the other group purchased the dietary fiber, oligosaccharide, and saccharide/lipid regulating nutrient food ("TABION" (registered) in a 10-day period. Trademark), α: below, T 〇:) (Non-Patent Document 5: Saito Mari, intravenous enteral nutrition, 23 (supple issue), 3 1 1, 2008). The main nutritional composition of Τα is shown in Table 10. As a result of the test, the blood glucose level in the administration (one hour before the end of the administration) was lower than that of the invented group (Fig. 6). Further, the nitrogen in the body of the present invention group was well maintained (Fig. 7), and the body weight of the product group having excellent nutritional balance was high in the case of becoming longer during the breeding period (Fig. 8), and the nutritional balance of the product of the present invention was effectively verified. In patients with abnormal glucose tolerance, vascular disorders or decreased blood flow due to metabolic abnormalities may cause sutures after surgery or acne due to prolonged bed rest. The treatment of trauma or hemorrhoids is indispensable for nutritionally balanced nutrients, and the malnutrition caused by poorly balanced nutrient intake increases the risk of such diseases, leading to prolonged healing. The nutritional composition of the present invention can suppress hyperglycemia after ingestion and can appropriately maintain a nutritional state. It is very useful for prevention of wounds, acne, or promotion of healing. -41 - 200942181 Table 10 Composition of purchased product Τα (200kCal/200ml) Raw material name Usage unit Milk protein 8.0 g of isoleucine • Creramamic acid saccharide 22 g Isomaltulose • Gram trehalose克 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维 纤维About 2 times the sufficiency rate of the foraging intake recommendation recommended amount) Experiment 7 GK rats (Japanese SLC (stock)) exhibiting a diabetic model with abnormal glucose tolerance were placed in a low-nutrient state, and the nutritional effects of the composition of the present invention were verified. That is, a 5-week-old GK mouse was administered with a protein-free mouse for 21 days to prepare a model rat having a low nutritional status against abnormal sugar. The rats were divided into two groups, and the liquid-like composition of Example 1 was administered to a group using a dispensing nozzle of 20 kcal/100 g BW· on the first day and 25 kcal/100 g BW after the third day. Another group was administered Τα for a total of 8 days. The Τα is not formulated with isomaltulose, trehalose or free isoleucine or free leucine in the saccharide, and no medium chain fatty acid triglyceride is formulated. Further, the ratio of the ω6 fatty acid/ω3 fatty acid is 3.6 - 42 to 200942181. As a result of carrying out the test, the weight of the product of the present invention which was excellent in nutritional balance during the period of the breeding period became high (Fig. 9). Further, it was confirmed that the present invention is not only a composition for administration, but also a nutritionally balanced composition even when taken orally. Experiment 8

Experiments were performed using GK mice (25-week-old male, Sakamoto SLC (stock)) in a diabetic model rat with abnormal sugar tolerance. For the fasted 18-hour rat, the nutritional composition of the present invention formulated in Example 1 was administered at 8 kcal/kg, and the nutritional composition A of undistributed free isoleucine and isomaltulose was administered at 6 kcal/kg. And measuring blood sugar (measurement machine: Fuji DRYCHEM 5 5 00 > Fujifilm (share) system). The blood glucose sputum after administration of the present invention showed the same blood glucose shift irrespective of the amount of the nutritional composition A (p = 〇.05, t test, Fig. 10). This result shows that the present invention having a blood sugar sputum inhibitory effect can absorb more energy or nutrients than a nutrient composition which does not take into consideration the increase in blood sugar sputum. In the case of the ingestion of the nutritional composition which is not inhibited by the increase in the blood sugar level, only 225 ml of the present invention can be ingested at a time, which is about 1.3 times that of the present invention. The increase in the intake of the present invention, which is a nutrient composition excellent in nutritional balance, which does not increase blood sugar levels, contributes to maintaining and improving the nutritional status of diabetic patients. Among them, in the case of a diabetic patient whose nutritional status is deteriorated, the present invention is a very useful composition which can be administered with a well-balanced high calorie. -43- 200942181 [Simplified Schematic Description] Fig. 1 is a diagram showing the effect of the isomaltulose to prepare the nutritional compositions A to C, and the blood glucose levels after oral administration. Fig. 2 is a graph showing the transition of blood glucose after oral administration of the present invention and the nutritional composition A formulated in Example 1. Fig. 3 is a graph showing changes in blood glucose after oral administration of the present invention and the nutritional composition D formulated in Example 2. Fig. 4 is a graph showing the rate of change of hemoglobin Ale after long-term oral administration of the nutritional composition E and the nutritional composition F. Fig. 4 is a graph showing the rate of change of hemoglobin Ale after long-term oral administration of the powdery inventive product of Example 1 and nutritional composition A. Fig. 6 is a graph showing blood glucose levels in the administration of the present invention prepared in Example 1 and the purchased Τα. Fig. 7 is a graph showing the nitrogen output of the inventive product prepared in Example 1 and the purchased Τα. Fig. 8 is a graph showing the change in body weight after administration of the inventive product prepared in Example 1 and the purchased Τα. Fig. 9 is a graph showing the rate of increase in body weight of the inventive product prepared in Example 1 after oral ingestion of the commercially available Τα2. Fig. 10 is a graph showing the transition of blood glucose after administration of the present invention (8 kcal/kg B.W.) and nutritional composition A (6 kcal/kg B.W.) prepared in Example 1. -44-

Claims (1)

200942181 VII. Patent application scope 1. A nutritional composition for suppressing hyperglycemia, which is a nutrient composition containing a nitrogen source, a lipid and a saccharide, characterized in that the nitrogen source contains free isoleucine and/or free bright amine. Acid, lipid containing medium chain fatty acid triglyceride, saccharide containing palatinose and/or trehalose 2. The nutritional composition of claim 1 is equivalent to nutrition per 100 kcal The composition contains 0.05 to 2.0 grams of free isoleucine and/or free leucine. The nutritional composition according to claim 1 or 2, wherein the fatty acid residue constituting the medium chain fatty acid triglyceride has a carbon number of 6 to 12. 4. The nutritional composition of claim 3, wherein the carbon number of the fatty acid residue constituting the medium chain fatty acid triglyceride is 8 and/or 10 5. As in any of claims 1 to 4 of the patent application scope The nutritional composition of the item, wherein the content of the medium chain fatty acid triglyceride is 5 to 75 in the total fat 6. The nutritional composition according to any one of claims 1 to 5, wherein the content of isomaltulose and/or trehalose in the saccharide is 50% by mass or less. 7. The nutritional composition according to any one of claims 1 to 6, wherein the mass ratio of isomaltulose and/or trehalose to free isoleucine and/or free leucine is 1 /75~4/1. 8. The nutritional composition according to any one of claims 1 to 7, which is used in combination with an insulin secretion stimulating substance. The nutrient composition of any one of the first to eighth aspects of the invention, wherein the nutrient composition is in the form of a powder, a granule, a plate, a rod, a gel or a liquid. 1 〇 The nutritional composition according to any one of claims 1 to 8, wherein the nutritional composition is in the form of a fluid for enteral use. 11. The nutritional composition according to any one of claims 1 to 8, wherein the nutritional composition is contained in a container. 12. The nutritional composition of claim 11, wherein the nutritional composition of 300 to 600 ml is contained in a container. 13. The nutritional composition according to any one of claims 1 to 12, which is produced by a step-controlled manufacturing step for suppressing oxidation or decomposition of a content by light, air or heating. The nutrient composition is contained in a container composed of a packaging material capable of suppressing deterioration due to oxygen, oxygen, and light during storage. 14. The nutritional composition according to any one of claims 1 to 13, wherein the nutritional composition has a calorie concentration of 1.5 kcal/ml or more. 15. The nutritional composition according to any one of claims 1 to 14, wherein the nutritional composition has a viscosity of 500 mPa·s or more. 16. A nutritional composition according to any one of claims 1 to 15 for use in the prevention and treatment of acne, wounds. 17. The nutritional composition according to any one of claims 1 to 16, which is used for nutritional management before and after surgery. 18. The nutritional composition according to any one of claims 1 to 17, which is for use in reducing or preventing oxidative stress caused by hyperglycemia. -46- 200942181 19. The nutritional composition according to any one of claims 1 to 18, which contains 35 to 155 mg of potassium and 20 to 100 mg of phosphorus per 100 kcal for use by kidney patients with hyperglycemia . -47-